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Abstract: Diethyldithiocarbamate Copper II (DDC-Cu) has shown potent anticancer activity against
a wide range of cancer cells, but further investigations are hindered by its practical insolubility in
water. In this study, inclusion complexes of DDC-Cu with hydroxypropyl beta-cyclodextrin (HP) or
sulfobutyl ether beta-cyclodextrin (SBE) were prepared and investigated as an approach to enhance
the apparent solubility of DDC-Cu. Formulations were prepared by simple mixing of DDC-Cu with
both cyclodextrin (CDs) at room temperature. Phase solubility assessments of the resulting solutions
were performed. DDC-Cu CD solutions were freeze-dried for further characterisations by DSC,
thermogravimetric analysis (TGA) and FT-IR. Stability and cytotoxicity studies were also performed
to investigate the maintenance of DDC-Cu anticancer activity. The phase solubility profile deviated
positively from the linearity (Ap type) showing significant solubility enhancement of the DDC-Cu in
both CD solutions (approximately 4 mg/mL at 20% w/w CD solutions). The DSC and TGA analysis
confirmed the solid solution status of DDC-Cu in CD. The resulting solutions of DDC-Cu were
stable for 28 days and conveyed the anticancer activity of DDC-Cu on chemoresistant triple negative
breast cancer cell lines, with IC50 values less than 200 nM. Overall, cyclodextrin DDC-Cu complexes
offer a great potential for anticancer applications, as evidenced by their very positive effects against
chemoresistant triple negative breast cancer cells.
Keywords: diethyldithiocarbamate copper II; beta-cyclodextrin; chemoresistance; triple negative
breast cancer; solubility
1. Introduction
Diethyldithiocarbamate copper (II) (DDC-Cu) consists of two molecules of diethyldithi-
ocarbamic acid (DDC), a disulfiram (DS) metabolite, with one ion of copper II [1,2]. DS,
clinically used as an anti-alcoholism drug, has been recently shown to possess potent
anticancer activities against a wide range of cancers including colon, breast, lung, prostate,
ovarian, cervical and brain cancers [1,3,4]. Additionally, the anticancer activity of DS
includes effective termination of drug-resistant cancer stem cells (CSCs) and reverses
chemoresistance [3,5]. However, the biological instability of DS in bloodstream has severely
limited its clinical use in anti-cancer therapy [3]. Disulfiram chelates copper II to produce
the complex DDC-Cu (Figure 1). The formation of this complex generates reactive oxygen
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species (ROS), inducing cancer cell death [1]. However, the anticancer activity of DSF/Cu
is not limited to instantaneous stress induced by ROS but also includes other mechanisms
such as the inhibition of NF-κB pathways [2,6]. The anti-cancer activity of DSF is com-
pletely dependent on the supplementation of copper II [2,7]. Therefore, the preformed
complex DDC-Cu itself has shown strong cytotoxicity against cancer cells when applied
directly [1]. Interestingly, it has been reported that DS-copper complex (DDC-Cu) is a po-
tent proteasome inhibitor inducing apoptosis in cancer cells but not normal, immortalized
breast epithelial cells [2,8]. More recently, Liu et al. have shown that DS/Cu is specifically
toxic to breast cancer cell lines (MCF-7 and T47D) and spares normal cell lines (HeCV and
MCF10A) [9].
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Figure 1. The formation of diethyldithiocarbamate copper II (DDC-Cu) as a result of disulfiram (DS)
reaction with copper [3].
However, the realisation of DDC-Cu as a new anticancer therapeutic agent is limited
by its very poor solubility in water. Previous attempts to circumvent t is issue are mainly
ased on a “split” de ivery of both DDC (water-soluble) and a solution of copper salt. The
re ction between both was meant t take place at the cancer c lls to produce the anti-cancer
action of DDC-Cu [10]. However, this reaction was not localised to cancer tissue and
insoluble crystals of DDC-Cu were still instantly formed, reducing the effective fraction [1].
Recently, Marengo et al. have followed similar “split” approach but by loading copper salts
to the lipid phase of PEGylated hyaluronic acid liposome encapsulating saturated solution
of DDC-sodium [11]. This method might theoretically offer a slight enhancement in the
solubility of DDC-Cu in liposomal dispersions; however, no long-term stability was proven.
The lipid bilayer would be depleted of Cu2+ chelated by DDC, consequentl , DDC-Cu
crystals might be precipitated or adsorbed onto the external liposomal urfaces [11].
CDs are cyclic oligosaccharides produced by the enzymatic degradation of starch,
where glucose residues link together by α-1,4 glycosidic bonds and form macrocyclic
molecules. According to the number of glucose subunits, CDs are categorized into α-CD,
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β-CD, and γ-CD, consisting of 6, 7, and 8 glucopyranose units, respectively [12,13]. The
unique truncated-cone-shaped structure of CDs, with hydrophilic surfaces and hydropho-
bic cavities, enabled them to form inclusion complex with poorly soluble drugs. The
resulting CD-drug inclusion complexes are known to enhance drug solubility, aqueous
stability, and shelf-life [14–16]. Furthermore, hydroxypropyl beta-cyclodextrin (HP) and
sulfobutyl ether beta-cyclodextrin (SBE) were classified by FDA as inactive pharmaceutical
excipients, i.e., both could be used in parenteral formulations with lower cytotoxic effects
compared to that of β-CD [14,17,18].
Despite the predominant interest in the wide spectrum anticancer activity of disulfiram
in the presence of copper, there has been limited research on proposing the resulting
complex DDC-Cu for cancer treatment. This is mainly due to the fact that this anticancer
material is not only practically insoluble in water but also cumbersome when loaded to
liquid formulations. Therefore, the development of stable water solution of DDC-Cu is
needed to allow further investigations on the potential use of this complex in the treatment
of cancer. In this study, we aim to report the preparation and characterization of inclusion
complexes formed by DDC-Cu and beta-CD derivatives HP or SBE for enhanced apparent
solubility of DDC-Cu. The resulting formulations were freeze-dried (lyophilized) to assess
drug-in-solution stability and amenability to be used in novel anticancer applications. The
impact of inclusion on the cancer activity were also evaluated by MTT assay using triple
negative breast cancer cell lines.
2. Materials and Methods
2.1. Materials
Copper (II) Diethyldithiocarbamate (DDC-Cu) (molecular weight = 360.07 g/mole
and +97.0% purity) was purchased from Tokyo Chemical Industry Co., Ltd., Tokyo, Japan.
HP (molecular weight = 1555 g/mol) and SBE (molecular weight = 2242.05 g/mole) were
both purchased from Glentham, Wiltshire, UK. M.D. Anderson-Metastasis Breast cancer
(MDA-MB-231) and MDA-MB-231 resistant to paclitaxel (PAC) at 10 nM concentration
(MDA-MB-231PAC10) were obtained from Professor Weiguang Wang’s research Group,
University of Wolverhampton, Wolverhampton, UK. In detail, MDA-MB-231PAC10 was
developed from MDA-MB-231 (purchased from ATCC, Middlesex, Teddington, UK) using
a procedure reported previously [5]. Paclitaxel (+99.5%) was obtained from Alfa Aesar,
Lancashire, UK. Dulbecco’s modified Eagle’s medium (DMEM), Gibco™ fetal bovine
serum (FBS), penicillin streptomycin (Pen-Strep) antibiotic solution, non-essential amino
acid solution and L-glutamine (cell culture tested, 99.0–101.0%), ethanol (absolute and
70%), 50 mL centrifuge tubes (sterile), tissue culture flask 75 cm2 (sterile) and serological
pipettes (sterile) Gibco™ Trypsin-EDTA (0.25%), phenol red, sodium chloride (99.5%),
potassium chloride, potassium phosphate and sodium phosphate were purchased from
Fisher Scientific, Loughborough, UK. 3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium
Bromide (MTT) and Dimethyl sulfoxide (DMSO) were purchased form Glentham Life




Aqueous solutions of SBE or HP (1%, 5%, 10%, 15%, 20% w/w) were initially prepared
using HPLC-grade water. An excess amount of DDC-Cu was added separately to 1 mL
of the aforementioned solutions. The resulting mixtures were vortexed, sonicated at
room temperature for 2 h, then agitated at 250 rpm for 3 days at room temperature using
Stuart reciprocating shaker SSL2 (Cole-Parmer, Neots, UK). Subsequently, the mixtures
were centrifuged (Thermo Scientific Heraeus PIC017) for 10 min at 13,000 rpm. The
supernatants (0.5 mL) were transferred to Spin X centrifuge tube with cellulose acetate
filter (0.45 µm) and centrifuged again for 10 min at 13,000 rpm. The filtrates were further
diluted with HPLC-grade water, and UV absorbance was measured at 435 nm using a UV
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spectrophotometer (Evolution TM 220 series with INSIGHT TM software, Thermo Fisher
Scientific, Loughborough, UK). The DDC-Cu concentration was finally calculated based
on a linear equation from a standard calibration curve of DDC-Cu in DMSO. The LOD
and LOQ for DDC-Cu, which were predicted from the calibration curve equation, were
0.06 mg/L and 0.188 mg/L, respectively. The %RSD of the repeatability test at 100 mg/L
drug concentration was less than 1.0, whereas the %RSD of the ruggedness test for the
same drug concentration is less than 2.0. Full validation of the analytical methods is
added as supplementary materials (Table S1 and Figure S1). In addition, all results were
confirmed using HPLC analysis according to our method described previously [1]. In Brief,
UltiMate 3000 UHPLC (Thermo Fisher Scientific, Loughborough, UK) with Accucore C18
4.6 × 150 mm column with a 2.6 µm particle size (Thermo Fisher Scientific, Loughborough,
UK) were used. The mobile phase comprised 90% HPLC-grade methanol and 10% HPLC-
grade water. The flow rate was 0.5 mL/min, and UV detection was performed at 275 and
435 nm with an injection volume of 20 µL.
2.2.2. Freeze-Drying
Samples (10 mL) of the above DDC-Cu cyclodextrin solutions (15% and 20% w/v) were
frozen at −80 ◦C for 12 h then freeze-dried under negative pressure of 0.06 ± 0.01 using
Lyotrap LTE freeze dryer (LTE Scientific Ltd, Oldham, UK) for 72 h. The samples (Table 1)
were stored at room temperature for further studies.
Table 1. Cyclodextrin (CD) concentration and acronyms of the freeze-dried formulations.
Sample Name CD Type CD Concentration (% w/w) DDC-Cu Concentrationmg/mL (Mean ± SD; n = 3)
SBE15 SBE 15 2.11± 0.03
SBE20 SBE 20 3.85± 0.09
HP15 HP 15 2.51 ± 0.06
HP20 HP 20 3.85 ± 0.07
2.2.3. Differential Scanning Calorimetry (DSC) Analysis
DSC analysis of DDC-Cu, SBE, HP and freeze-dried formulations was performed using
a differential scanning calorimeter (214 Polyma, Netzsch, Selb, Germany). Samples were
weighted and crimp-sealed in aluminium led pierced-pans. Tests were carried out under
nitrogen gas flow (20 mL/min) over a temperature range of 0–300 ◦C and at a heating
rate of 10 ◦C/min. The thermograms were analysed using Proteus Analysis software
(version 7.0.1).
2.2.4. Thermogravimetric Analysis (TGA)
TGA was carried out using TG 209 F3 Tarsus model (Netzsch, Selb, Germany) in order
to determine the moisture content of freeze-dried samples. Samples (3–7 mg) were loaded
on an open fused silica crucible suspended from a microbalance and heated dynamically
from 25 to 110 ◦C at 10 ◦C/min heating rate. The samples were kept at 110 ◦C for 3 min then
heated to 300 ◦C at 10 ◦C/min. The resulting data were analysed using Proteus Analysis
software (version 6.1.0, Netzsch, Selb, Germany).
2.2.5. Fourier Transform Infrared Spectroscopy (FTIR)
Infrared spectra were obtained using Spectrum Nicolet iSF FTIR Spectrophotometer
(Thermo Scientific, Loughborough, UK), supported with iDF ATR. Small amount of each
sample was directly loaded into the instrument without any treatment. The analysed
spectra showed the % transmittance of different samples versus the wavenumbers range of
4000 to 650 cm−1. The data were obtained by OMNIC 9 software and presented by Excel.
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2.2.6. Drug Solution Stability Study
The stability of freshly prepared and reconstituted solutions listed on Table 1 was as-
sessed over 28 days. For reconstituted solutions, the freeze-dried samples were redissolved
in HPLC-grade water without any further shaking or stirring. Samples were stored at room
temperature and at appropriate intervals (weekly), aliquots of 0.5 mL were filtered and
tested by UV spectrophotometer as explained above. The stability of DDC-Cu in solutions
were confirmed by HPLC analysis as described earlier.
2.2.7. Cytotoxicity Studies
The cytotoxic effect of SBE20 and HP20 freeze-dried formulations on breast cancer cells
was assessed in vitro. Living cells, indicated by metabolic activity, were estimated using
an MTT assay and presented as a percentage of the non-treated cells [19]. MDA-MB-231
and MDA-MB-231PAC10 cells were seeded in 96-well plates at a density of 10 × 103 cells
for MDA-MB-231 and 5 × 103 cells for MDA-MB-231PAC10 in Dulbecco’s modified Eagle’s
medium (DMEM) with 10% FBS, 1 mM sodium pyruvate, 2 mM L-glutamine, 50 IU/mL
penicillin, 50 µg/mL streptomycin and 0.1 mM non-essential amino acids. Cells were
incubated for 24 h (Heracell 150i CO2 incubator, Thermo Scientific, Loughborough, UK)
at 37 ◦C with 5% CO2, then treated with full growth media containing reconstituted
formulations. Blank CDs solutions were used as negative controls and DDC-Cu was used as
a positive control. After 72 h, all wells were treated with a standard 3-(4,5-Dimethylthiazol-
2-yl)-2,5-Diphenyltetrazolium bromide (MTT) assay as previously described [20]. The
experiments were carried out in triplicate and the IC50 values were calculated.
2.2.8. Statistical Analysis
Statistical significance was measured using the one-way analysis of variance (ANOVA)
and student’s t-tests as appropriate. All values were expressed as the mean ± standard
deviation. Values of p < 0.05 were regarded as significantly different.
3. Results and Discussion
3.1. Solubility Studies
The intrinsic solubility of DDC-Cu was below the limit of detection of both UV
spectrometry (supplementary materials) and even HPLC methods (data not shown). Thus,
the intrinsic solubility was predicted in water using DMSO as a co-solvent by adopting
methods of prediction reported by Vithlani et al. [21]. Our results confirmed that DDC-Cu
was practically insoluble in water as the predicted intrinsic solubility was 0.0007 mg/L
(Figure S2).
The solubility of DDC-Cu in different concentrations of HP and SBE was explored; the
higher the CD concentration, the higher the apparent solubility of DDC-Cu (Figure 2). The
solubility of DDC-Cu had a polynomial relationship with the increasing concentrations of
both types of CD.
According to Higuchi and Connors’ model, this type of relationship between CDs
and DDC-Cu that deviates positively from linearity was Ap-type phase (Figure 2B) [22].
Ap-type phase was usually obtained when water soluble CDs, such as HP and SBE, were
used, and indicated that drug solubility increased in a non-linear fashion with increasing
CDs concentration. This positive deviation suggests that the employed CDs were propor-
tionately more effective at higher concentrations [12]. This might also be explained by the
superior drug–CD interaction compared to CD–CD interactions. Normally, the physic-
ochemical properties of the guest molecule and the type of CD (the host) predominate
the outcome of this competition between both interactions [23]. The prepared solutions
were clear with different degree of yellow, but become dark brown or black at higher
concentrations, hence, 50-fold dilutions were used for imaging (Figure 2C).
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It is worth mentioning that the pH values for all CD solutions remained stable within
the range of 5–7 throughout the study (Table S2). This might suggest the suitability of CD
formulations for clinical applications.
As shown in Figure 2A, for both 20% w/w CD solutions, the solubility of DDC-Cu has
reached approximately 4 mg /mL. This provides not only unprecedented concentration of
DDC-Cu but also potentially stable freeze-dried formulations and stable solutions (tested
for 28 days as shown below). Further ore, this solubility value is appropriate for further
investigation on anticancer activity of this ingredient. For example, the minimum limit of
solubility to initiate pharmacokinetic studies on rats or mice is 2.0 mg/mL [24].
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3.2.2. Thermogravimetric Analysis (TGA)
The thermal stability of the formulations compared to raw materials was further
investigated using thermogravimetric analysis (TGA). Figure 4 shows that pure DDC-Cu
experienced three stages of weight loss: early stage of 40 to 100 ◦C, the weight loss was
due to loss of surface adsorbed and hydrogen bond water. This stage is less noticeable for
CD raw materials and formulations. No further significant decrease in weight is shown
during the second stage for DDC-Cu (100–190 ◦C) and CD raw materials and formulations
(100–260 ◦C). Starting at approximately 190 ◦C, the third stage for DDC-Cu involves
a sharp loss of the total weight at 290 ◦C. This might be explained by the cleavage of
chemical bonds between DDC and Cu2+, followed by the degradation of reactive DDC to
diethylamine and carbon disulfide [26]. The third stage starts at two different points for
CD formulations; at approximately 260 ◦C SBE formulations, while HP formulations are
expected to start above 300 ◦C [27]. The difference between TGA profiles for both beta CDs,
owning to different chemical structures, have already been reported in literature [27–29].
More importantly, SBE15 and SBE20 formulations showed more resistance to degradation
than raw SBE, by around 15 ◦C between both points where a sharp drop in weight occurred
(Figure 4A). This may be due to the fact that the interaction between DDC-Cu and SBE
resulted in stronger complex formation, demanding more heat to break. Interestingly, the
distinctive degradation peak of DDC-Cu is not shown by both CDs formulations, which
might constitute an evidence of the protection provided by the CDs as a stabilising host for
DDC-Cu [30].
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Figure 4. Thermogravimetric Analysis (TGA) thermographs of (A) SBE-CD freeze dried formulations, SBE-CD and DDC-Cu
and (B) HP-CD freeze dried formulations, HP-CD and DDC-Cu.
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3.2.3. Fourier Transform Infrared Spectroscopy (FTIR)
Figure 5 shows the FTIR spectra of the freeze-dried formulations of SBE and HP,
pure DDC-Cu and pure CDs. The IR spectrum of DDC-Cu shows a strong absorption
band at 1504 cm−1 corresponding to the C-N bond, which indicates its partial double
bond nature. There was no difference between pure CDs spectra and the corresponding
freeze-dried formulations, where none of DDC-Cu vibration bands stands significantly
in the CD complexes. The disappearance of DDC-Cu vibration bands in the formulations
might mainly be due to the fact that the formulation content of DDC-Cu was lower than the
detection limit of our FT-IR kit. However, the restriction of bending and stretching vibration
of guest molecules by the formation of inclusion complexes have also been reported [31].
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3.3. Drug Solution Stability Studies
Th r pid precipitation of DDC-Cu in the form of crystals is a ma n challenge during
the prepar ion of any formulation incorporating this material. In addition, most of the
previous attempts have failed to produce stable solutions of DDC-Cu that are potentially
suitable for therapeutic administration. The stability of freshly prepared and reconstituted
solutions was performed over 28 days to confirm that there was no precipita ion, crystalli-
sation or degradation of DDC-Cu. As shown by Figure 6, all solutions were stabl for 28
days without any significant change (p > 0.05) on DDC-Cu c centration. Compared to
other nanomedical formulations [10,32], no sign of precipitation nor crystallisation was
shown. These results were not unexpected for CDs used successfully in pharmaceutical
research as solubility enhancers of hydrophobic drugs/ingredients [33,34].
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Figure 6. Solution state stability studies of the freshly prepared (A) and reconstituted (B) DDC-Cu CD solutions. For both,
the axes y represents the percentage remained of solubilized DDC-Cu in solution.
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3.4. Cytotoxicity Studies
Triple-negative breast cancer (TNBC) is an aggressive type of cancer due to the lack of
molecular markers such as oestrogen receptors and progesterone receptors [35]. Further-
more, TNBC can develop chemoresistance after repetitive exposure to first line chemother-
apy agents such as Paclitaxel (PAC), an anti-cancer drug [5,36–38]. This acquired chemore-
sistance then becomes the major challenge in chemotherapy. In this study, two types of
TNBC cell lines: (1) MDA-MB-231, the sensitive and (2) MDA-MB-231PAC10, the resistant
cell line were used to assess the cytotoxic effect of DDC-Cu and its formulations. In addition
to its high resistance to PAC, MDA-MB-231PAC10 has been reported to be cross-resistant to
drugs such as cisplatin, docetaxel and doxorubicin [5].
As shown in Figure 7, MDA-MB-231 cells were sensitive to the cytotoxic effect of PAC
and DDC-Cu. However, MDA-MB-231PAC10 showed high resistant to PAC (IC50 >1000 nM)
but completely terminated by DDC-Cu (p < 0.05) (Figure 7C). These results confirm that
DDC-Cu had the ability to overcome chemoresistance of MDA-MB-231PAC10. Interestingly,
Liu et al. (2013) have reported similar results but after applying disulfiram in combination
with CuCl2 on both MDA-MB-231PAC10 [5]. This also supports our previous findings
showing that the mechanism of action for the combined disulfiram and CuCl2 may not
be limited to ROS and that DDC-Cu has a strong and prolonged anti-cancer activity (i.e.,
potential druggable anti-cancer candidate) [1].
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The cytotoxic effect of inclusion complexes of DDC-Cu (HP20 and SBE20) was also
assessed. As shown in Figure 8, HP20 and SBE20 elicited cytotoxic activity similar to that
of free DDC-Cu, used as a positive control, on both cell lines. Furthermore, there were no
significant differences amongst HP20 and SBE20, and DDC-Cu (p > 0.05), whereas empty
CDs solutions had no cytotoxic activity on both cells. Despite the apparent differences
in IC50 values between both CDs HP20 and SBE20, and both cell lines MDA-MB-231,
and MDA-MB-231PAC10, our statistical analysis confirmed that there was no significant
difference to report (p > 0.05) (Figure 8).




Figure 8. Survival curves (MTT assay) of triple negative breast cancer cell lines MDA-MB-231 (A) and MDA-MB-231PAC10 
(B) after 72 h of exposure to increasing concentration of DDC-Cu formulations. (C) The IC50 values of DDC-Cu and for-
mulations on both breast cancer cell lines (n = 3 ± SD). 
4. Conclusions 
The use DDC-Cu as an anticancer drug has always been challenged by its poor aque-
ous solubility. In this work, we have shown that the solubility of DDC-Cu may be im-
proved using CD inclusion complexes. The freeze-dried formulations were readily dis-
solved in water yielding DDC-Cu solutions of high stability for 28 days. The thermal char-
acteristics of the freeze-dried formulations supported the formation of inclusion com-
plexes with the DDC-Cu molecules interacting CD molecules in a solid solution form. The 
MTT cytotoxicity study showed a strong toxic effect of the freeze-dried formulations on 
both MDA-MB-231 (sensitive) and MDA-MB-231PAC10 (chemoresistant) breast cancer cell 
lines similar to that of free DDC-Cu. Our results report that cyclodextrin DDC-Cu com-
plexes have a great potential for further anticancer applications, especially, in vivo stud-
ies. 
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4. Conclusions
The use DDC-Cu as an anticancer drug has always been challenged by its poor aque-
ous solubility. In this work, we have shown that the solubility of DDC-Cu may be improved
using CD inclusion complexes. The freeze-dried formulations were readily dissolved in
water yielding DDC-Cu solutions of high stability for 28 days. The thermal characteristics
of the freeze-dried formulations supported the formation of inclusion complexes with the
DDC-Cu molecules interacting CD molecules in a solid solution form. The MTT cytotoxicity
study showed a strong toxic effect of the freeze-dried formulations on both MDA-MB-231
(sensitive) and MDA-MB-231PAC10 (chemoresistant) breast cancer cell lines similar to that
of free DDC-Cu. Our results report that cyclodextrin DDC-Cu complexes have a great
potential for further anticancer applications, especially, in vivo studies.
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